Skip to main content
. 2020 Aug 4;59(23):2971–2979. doi: 10.2169/internalmedicine.4447-20

Table 4.

Endoscopic and Histological Findings at the First and Last Endoscopy Session in Asymptomatic EE with Long-term Follow up of More than Three Years.

Diffuse EE Localized EE
first EGD last EGD p value first EGD last EGD p value
n 14 14 - 7 7 -
mean age at the first diagnosis (range, years) 52 (37-74) - - 52 (44-74) - -
mean number of follow-up endoscopy 5 (3-7) 4 (3-6)
median follow up period (range, months) 61 (36-82) 49 (39-72)
progression to symptomatic EE - 0 - - 0 -
PPI users (%) 1 (7.1) 5(35.7) ns 0 1 (14.3) ns
prevalence of endoscopic findings
rings (%) 8 (57.1) 8 (57.1) ns 2 (28.6) 1 (14.3) ns
furrows (%) 10 (71.4) 7 (50.0) ns 6 (85.7) 1 (14.3) 0.0291*
exudate (%) 12 (85.6) 8 (57.1) ns 3 (42.9) 1 (14.3) ns
edema (decreased vascularity) (%) 14 (100) 12 (85.7) ns 7 (100) 6 (85.7) ns
stricture (%) 0 (100) 0 (100) ns 0 0 ns
endoscopic score (median, range)
rings 1 (0-2) 1 (0-2) ns 0 (0-1) 0 (0-1) ns
furrows 1.5 (0-2) 0.5 (0.2) ns 2 (0-2) 0 (0-2) ns
exudate 1 (0-2) 1 (0-1) 0.0313** 0 (0-1) 0 (0-1) ns
edema (decreased vascularity) 1 (1-1) 1 (0-1) ns 1 (1-1) 0 (0-1) ns
stricture 0 (0-0) 0 (0-0) ns 0 (0-0) 0 (0-0) ns
total score 4 (1-7) 3 (0-7) ns 3 (2-5) 1 (0-4) 0.0156**
number of esophageal eosinophilia (/HPF)(median, range) 57.5 (18-118) 76 (0-110)*** ns 54 (33-162) 10 (0-46)*** ns

*Fisher’s exact probability test.

**Wilcoxon’s signed rank test.

***Esophageal biopsies were not obtained from 5 of 14 diffuse and 2 of 7 localized patients in the last endoscopy.

EE: esophageal eosinophilia, EGD: esophagogastroduodenoscopy, PPI: proton pump inhibitor